CL2019000538A1 - Derivados de imidazol y su uso en tratamiento de enfermedades autoinmunes, inflamatorias o canceres. - Google Patents

Derivados de imidazol y su uso en tratamiento de enfermedades autoinmunes, inflamatorias o canceres.

Info

Publication number
CL2019000538A1
CL2019000538A1 CL2019000538A CL2019000538A CL2019000538A1 CL 2019000538 A1 CL2019000538 A1 CL 2019000538A1 CL 2019000538 A CL2019000538 A CL 2019000538A CL 2019000538 A CL2019000538 A CL 2019000538A CL 2019000538 A1 CL2019000538 A1 CL 2019000538A1
Authority
CL
Chile
Prior art keywords
treatment
inflammatory
autoimmune
imidazole derivatives
cancerous diseases
Prior art date
Application number
CL2019000538A
Other languages
English (en)
Inventor
Katherine Louise Jones
Andrew Baxter
John Alexander Brown
David Hirst
Philip Humphreys
Vipulkumar Kantibhai Patel
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of CL2019000538A1 publication Critical patent/CL2019000538A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPUESTOS DE FÓRMULA (I) Y SALES DE LOS MISMOS, EN LA QUE R1, R2, R3 Y A SON COMO SE DEFINEN EN EL PRESENTE DOCUMENTO. SE HA DESCUBIERTO QUE LOS COMPUESTOS DE FÓRMULA (I) Y SALES DE LOS MISMOS INHIBEN LA UNIÓN DE LA FAMILIA BET DE PROTEÍNAS QUE CONTIENEN BROMODOMINIOS A, POR EJEMPLO, RESIDUOS DE LISINA ACETILADOS Y, POR TANTO, PUEDEN TENER USO EN TERAPIA, POR EJEMPLO, EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNITARIAS E INFLAMATORIAS, TALES COMO ARTRITIS REUMATOIDE; Y CÁNCERES.
CL2019000538A 2016-09-02 2019-02-28 Derivados de imidazol y su uso en tratamiento de enfermedades autoinmunes, inflamatorias o canceres. CL2019000538A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1614934.6A GB201614934D0 (en) 2016-09-02 2016-09-02 Chemical compounds

Publications (1)

Publication Number Publication Date
CL2019000538A1 true CL2019000538A1 (es) 2019-05-17

Family

ID=57140084

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000538A CL2019000538A1 (es) 2016-09-02 2019-02-28 Derivados de imidazol y su uso en tratamiento de enfermedades autoinmunes, inflamatorias o canceres.

Country Status (24)

Country Link
US (1) US20190175571A1 (es)
EP (1) EP3507283A1 (es)
JP (1) JP2019526577A (es)
KR (1) KR20190042701A (es)
CN (1) CN109790147A (es)
AR (1) AR109487A1 (es)
AU (1) AU2017317724A1 (es)
BR (1) BR112019004241A2 (es)
CA (1) CA3035312A1 (es)
CL (1) CL2019000538A1 (es)
CO (1) CO2019001871A2 (es)
CR (1) CR20190106A (es)
DO (1) DOP2019000047A (es)
EA (1) EA201990410A1 (es)
GB (1) GB201614934D0 (es)
JO (1) JOP20190029A1 (es)
MA (1) MA46085A (es)
MX (1) MX2019002491A (es)
PE (1) PE20190478A1 (es)
PH (1) PH12019500460A1 (es)
SG (1) SG11201901673SA (es)
TW (1) TW201817724A (es)
UY (1) UY37393A (es)
WO (1) WO2018041947A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20190101A (es) 2016-09-02 2019-07-04 Ironwood Pharmaceuticals Inc Estimuladores de sgc
CN111686107B (zh) * 2020-07-16 2021-06-08 中国农业科学院兰州兽医研究所 化合物plx51107用于制备预防或治疗非洲猪瘟药物的新用途
CN111588725B (zh) * 2020-07-16 2021-06-08 中国农业科学院兰州兽医研究所 化合物arv-825用于制备预防或治疗非洲猪瘟药物的新用途
CN111686114B (zh) * 2020-07-16 2021-06-08 中国农业科学院兰州兽医研究所 化合物i-bet-762用于制备预防或治疗非洲猪瘟药物的新用途
CN111588721B (zh) * 2020-07-16 2021-06-08 中国农业科学院兰州兽医研究所 化合物zl0580用于制备预防或治疗非洲猪瘟药物的新用途
WO2024018423A1 (en) * 2022-07-21 2024-01-25 Tay Therapeutics Limited Pyrroles and imidazoles as bet protein inhibitors
CN117257964B (zh) * 2023-10-25 2024-04-02 苏州大学 基于碳酸氢铵的微波诱导吲哚美辛原位无定形化增溶技术

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3406329A1 (de) * 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
DE4034060A1 (de) * 1990-10-26 1992-04-30 Basf Ag Biskationische azofarbstoffe
DE19809994B4 (de) * 1997-03-19 2006-02-09 Basf Ag Clathrate von Bis-[6-hydroxy-4-methyl-5-(3-methylimidazolium-1-yl)-3-(phen-4-ylazo)-pyridin-2-on]ethylen
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
PE20060285A1 (es) * 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
KR101404360B1 (ko) * 2006-09-05 2014-06-09 교와 핫꼬 기린 가부시키가이샤 이미다졸 유도체
US8129394B2 (en) * 2008-03-21 2012-03-06 Novartis Ag Heteroaryl-substituted imidazole compounds and uses thereof
CN102099036B (zh) * 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CA2789474A1 (en) * 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
AU2013365926B9 (en) * 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
CN104788423B (zh) * 2015-03-13 2016-10-26 成都理工大学 一种新的囊性纤维化跨膜传导调节因子抑制剂
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds

Also Published As

Publication number Publication date
JOP20190029A1 (ar) 2019-02-25
AU2017317724A1 (en) 2019-03-21
PH12019500460A1 (en) 2019-12-16
SG11201901673SA (en) 2019-03-28
TW201817724A (zh) 2018-05-16
EP3507283A1 (en) 2019-07-10
BR112019004241A2 (pt) 2019-06-04
MA46085A (fr) 2019-07-10
AR109487A1 (es) 2018-12-12
UY37393A (es) 2018-03-23
JP2019526577A (ja) 2019-09-19
EA201990410A1 (ru) 2019-09-30
GB201614934D0 (en) 2016-10-19
CO2019001871A2 (es) 2019-03-08
MX2019002491A (es) 2019-07-08
CR20190106A (es) 2019-05-02
US20190175571A1 (en) 2019-06-13
CN109790147A (zh) 2019-05-21
KR20190042701A (ko) 2019-04-24
DOP2019000047A (es) 2019-03-15
CA3035312A1 (en) 2018-03-08
PE20190478A1 (es) 2019-04-04
WO2018041947A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
CL2019000538A1 (es) Derivados de imidazol y su uso en tratamiento de enfermedades autoinmunes, inflamatorias o canceres.
CL2017002332A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
CO2017011484A2 (es) Inhibidores de bromodominio
CR20160229A (es) Inhibidires de bromodominio
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
ECSP20060827A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
CL2017000521A1 (es) Inhibidores de desmetilasa-1 específica a lisina
CR20150633A (es) Derivados del bipirazol como inhibidores jak
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
BR112015027951A2 (pt) arilquinazolinas
CL2016003350A1 (es) Inhibidores de demetilasa-1 especifica de lisina
CU24187B1 (es) Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
CL2012001821A1 (es) Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CR20200464A (es) Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
ECSP17010481A (es) Novedosas pirimidinas 2,5-sustituidas
BR112012023836A2 (pt) composto tricíclicos e inibidores de pbk contendo os mesmos
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos